Department of Dentistry, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, T6G2E1, Canada.
Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, T6G2E1, Canada.
Cancer Immunol Immunother. 2020 Aug;69(8):1423-1436. doi: 10.1007/s00262-020-02555-2. Epub 2020 Apr 3.
On-treatment steroids for countering immune checkpoint inhibitor-induced inflammatory responses (irAEs) are a hallmark of cancer immunotherapy. However, the suppressive nature of steroids has raised questions regarding their ability to compromise the function of the 'proliferative burst' of effector T cells induced by immune checkpoint antibodies. We investigated the effector functions and the co-inhibitory receptor profile of stimulated peripheral blood mononuclear cells (PBMCs) pre-treated with prednisone and dexamethasone alone or in the presence of anti-PD-1/CTLA-4 antibodies. Also, clinical analysis of a patient who exhibited irAEs following combination (anti-PD-1/CTLA-4) in the presence of glucocorticoids was done. We found that prednisone in contrast to dexamethasone did not compromise T cell cytokine production (IL-2, IFN-γ and TNF-α) and proliferation in the absence or presence of anti-PD-1/CTLA-4 antibodies, when a physiological concentration was used. Neither single prednisone treatment nor co-treatment with checkpoint inhibitors impacted the expression of co-inhibitory receptors PD-1, CTLA-4, TIM-3 and LAG-3. In contrast, dexamethasone treatment promoted downregulation of LAG-3 expression by T cells. In addition, co-treatment of PD-1 + Jurkat cells with prednisone and/or dexamethasone with anti-PD-1 before stimulation significantly reduced SHP-2 phosphorylation, indicative of increased T cell function. Our findings hereby demonstrate a differential steroid effect on T cell function, which should be taken into consideration for patients undergoing immunotherapy. Also, the clinical analysis of a patient who exhibited irAEs following combination (anti-PD-1/CTLA-4) therapy indicated complete metabolic response in the presence of glucocorticoids. Therefore, concomitant use of prednisone does not appear to interfere with the function of immune checkpoint blockade.
治疗中用于对抗免疫检查点抑制剂诱导的炎症反应 (irAEs) 的类固醇是癌症免疫治疗的标志。然而,类固醇的抑制作用引发了人们对其是否能够影响免疫检查点抗体诱导的效应 T 细胞“增殖爆发”功能的质疑。我们研究了单独使用泼尼松和地塞米松预处理或同时使用抗 PD-1/CTLA-4 抗体预处理的刺激外周血单核细胞 (PBMCs) 的效应功能和共抑制受体谱。此外,还对在糖皮质激素存在下联合(抗 PD-1/CTLA-4)治疗后出现 irAEs 的患者进行了临床分析。我们发现,与地塞米松相比,在使用生理浓度时,泼尼松不会影响 T 细胞细胞因子产生(IL-2、IFN-γ 和 TNF-α)和增殖,无论是否存在抗 PD-1/CTLA-4 抗体。单独使用泼尼松治疗或与检查点抑制剂联合治疗均不会影响共抑制受体 PD-1、CTLA-4、TIM-3 和 LAG-3 的表达。相比之下,地塞米松处理会促进 T 细胞中 LAG-3 表达的下调。此外,在刺激前用 PD-1+Jurkat 细胞与泼尼松和/或地塞米松以及抗 PD-1 联合处理可显著降低 SHP-2 磷酸化,表明 T 细胞功能增强。我们的研究结果证明了类固醇对 T 细胞功能的差异作用,这对于接受免疫治疗的患者应加以考虑。此外,对在联合(抗 PD-1/CTLA-4)治疗后出现 irAEs 的患者的临床分析表明,在糖皮质激素存在下存在完全代谢反应。因此,同时使用泼尼松似乎不会干扰免疫检查点阻断的功能。